TAFLUPROST
Tafluprost is a prostaglandin analog used in ophthalmic solutions to reduce intraocular pressure. It belongs to the class of medications known as prostaglandin F2? analogs. By increasing the outflow of aqueous humor, it helps in treating conditions such as glaucoma and ocular hypertension.-Tafluprost is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. -It is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
-The usual dosage is one drop of the Tafluprost ophthalmic solution in the affected eye(s) once daily in the evening. -Topical; one drop in conjuctival sac of affected eye every evening
Tafluprost is contraindicated in patients with known hypersensitivity to the drug or any of its components.
-Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). -Contact lenses should be removed prior to administration and can be reinserted 15 minutes after the administration of Tafluprost. -Close monitoring is required in patients with active intraocular inflammation as it may worsen with the use of prostaglandin analogs. Paediatric: Data not sufficient. Pregnancy: Category C. Lactation: Data not sufficient. Elderly: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
-Common side effects may include eye redness, itching, stinging, blurred vision, and changes in eyelash growth. Uncommon side effects may include iris pigmentation, darkening of the eyelid skin, and length/thickness changes of eyelashes. -Allergic conjunctivitis, cataract, dry eye, ocular pain, eyelash darkening, growth of eyelashes, vision blurred
-No significant drug interactions have been reported with Tafluprost. However, it is essential to inform healthcare providers about all medications being taken, including prescription, over-the-counter, and herbal supplements. -If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications.